Roche’s 89bio Buyout: Building A Combo-Ready Metabolic Franchise Beyond GLP

Roche Holding AG's acquisition of 89bio, Inc. to expand cardiometabolic offerings and drive growth beyond GLP-1. Click for more on RHHBY and ETNB.